So Taiwan won the day. At first the sale went well. Aslan, whose investors include Accuron Technologies, a unit of Singapore’s Temasek Holdings, and which specializes in experimental cancer drugs, completed its IPO in May, raising NT$1 billion ($33 …
( read original story …)